<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="570">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05153733</url>
  </required_header>
  <id_info>
    <org_study_id>N19IRM</org_study_id>
    <secondary_id>NL74131.031.20</secondary_id>
    <nct_id>NCT05153733</nct_id>
  </id_info>
  <brief_title>Improved Implant for Reconstruction Purposes After Mandibular Resection</brief_title>
  <acronym>RifRam</acronym>
  <official_title>Improved Implant for Reconstruction Purposes After Mandibular Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Netherlands Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study design: A single center non-randomized, prospective clinical feasibility study.&#xD;
&#xD;
      Study population: Study population is composed of 10 patients ineligible for a free-flap bone&#xD;
      reconstruction.&#xD;
&#xD;
      Intervention: The selected patients will receive the newly developed, patient-specific RIfRaM&#xD;
      mandibular implant.&#xD;
&#xD;
      Objective: The aim is to provide enough evidence through model analysis, physical tests and&#xD;
      clinical study of 10 patients that our new type of personalized mandibular implant is safe to&#xD;
      use, resulting in significantly fewer complications and can be practically placed during the&#xD;
      surgery, without any complications.&#xD;
&#xD;
      Main study parameters/endpoints: The study endpoint is to use the RifRaM without any implant&#xD;
      related complications and a perfect mandibular fit.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 29, 2021</start_date>
  <completion_date type="Anticipated">November 29, 2024</completion_date>
  <primary_completion_date type="Anticipated">November 29, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical fit</measure>
    <time_frame>intra-operative</time_frame>
    <description>good fit during surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complications</measure>
    <time_frame>implant loss in 1-year post-operational follow-up.</time_frame>
    <description>Implant related complications leading to implant loss</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Oral Cancer</condition>
  <arm_group>
    <arm_group_label>RIFRAM implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RIFRAM implant</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>RIFRAM implant</intervention_name>
    <description>Participants will receive the newly developed, patient-specific RIfRaM mandibular implant.</description>
    <arm_group_label>RIFRAM implant</arm_group_label>
    <other_name>COMMANDO</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years at time of study entry.&#xD;
&#xD;
          -  T4 oral cavity tumor with mandible invasion, requiring segmental mandibulectomy.&#xD;
&#xD;
          -  Reconstruction with free fibula flap not feasible because of any or a combination of&#xD;
             the following reasons:&#xD;
&#xD;
        oCT angiography of the legs and/or the neck shows severe stenosis of the ves-sels.&#xD;
&#xD;
          -  Previous medical history of severe atherosclerotic disease.&#xD;
&#xD;
          -  General health condition necessitating a shorter operation time.&#xD;
&#xD;
               -  Cases will be discussed in the multidisciplinary tumor board that they are&#xD;
                  eligible for composite resection but not eligible for free fibula flap.&#xD;
&#xD;
               -  Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are eligible for free fibula flap.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  General health condition does not allow surgery&#xD;
&#xD;
          -  History of psychiatric disability judged by the investigator to potentially hamper&#xD;
             compliance with the study protocol and follow-up schedule.&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek</name>
      <address>
        <city>Amsterdam</city>
        <state>NH</state>
        <zip>1082 MK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baris Karakullukcu, PhD</last_name>
      <phone>+31205122550</phone>
      <email>b.karakullukcu@nki.nl</email>
    </contact>
    <contact_backup>
      <last_name>Klaske van Sluis, PhD</last_name>
      <phone>+31205122550</phone>
      <email>k.v.sluis@nki.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 29, 2021</study_first_submitted>
  <study_first_submitted_qc>November 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>surgery</keyword>
  <keyword>COMMANDO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

